Introduction
Approximately 17 400 primary brain tumors are newly diagnosed each year in the US (Landis et al., 1998) . The incidence of malignant glial neoplasms account for more than 60% of primary adult brain tumors of which about 75% are glioblastoma multiforme (GBM) (Grade IV). Patients with GBM have median survivals of only 8-10 months (Curran et al., 1993) . Radiation therapy remains the single most effective adjuvant treatment for malignant astrocytomas (Salazar and Rubin, 1976; Walker et al., 1980) . However, most patients treated with standard radiation therapy alone have in-field recurrences that inevitably lead to the patient's death because no adequate salvage therapy exists (Hochberg and Pruitt, 1980; Wallner et al., 1989) . Radiation resistance of malignant gliomas is partly due to their vascular abundance. The upregulation of angiogenesis is a key event that accompanies glioma progression (Leon et al., 1996; Wesseling et al., 1997) . Phosphoinositol-3 kinase (PI3K)/Akt survival pathway has been found to be responsible for tumor promotion, aggressiveness, and resistance to both radiotherapy and BCNU-based chemotherapy in glioblastoma cells (Holland et al., 2000; Sonoda et al., 2001; Chakravarti et al., 2002; Ermoian et al., 2002) . Inhibition of the PI3K/Akt pathway radiosensitizes tumor vasculature in mouse glioma models, possibly by inhibiting radiation-activated Akt phosphorylation in endothelial cells (ECs) (Edwards et al., 2002; Tan and Hallahan, 2003) . Similar Akt activation was shown to be induced by ionizing radiation in a glioma cell line via the EGFR pathway (Chakravarti et al., 2002) . Therefore, blocking the prosurvival activity of PI3K/Akt that is induced by radiation may augment cytotoxic effects upon both glioma cells and its vasculature.
Mammalian target of rapamycin (mTOR) is a downstream target of Akt (Nave et al., 1999) . It was shown that vascular endothelial growth factor (VEGF)-stimulated human umbilical vein endothelial cells (HUVEC) proliferation was effectively inhibited by rapamycin, indicating that mTOR is a key molecule for EC survival (Yu and Sato, 1999) . mTOR may also be important for the survival of glioma cells since certain glioma cell lines were shown to be sensitive to rapamycin and its derivatives (Hosoi et al., 1998) . mTOR has also been shown to affect cells in numerous ways including decreased proliferation, increased apoptosis, and induction of autophagy, all of which appear to be cell line dependent (Munafo and Colombo, 2001; Huang and Houghton, 2003; Majumder et al., 2004) . The present study examined whether mTOR signaling is activated by irradiation and whether mTOR inhibitors, rapamycin and RAD001, could sensitizes glioma to radiotherapy by inhibiting either angiogenesis or tumor growth, and by which mechanism cell death occurs.
Results mTOR inhibitors, rapamycin and Rad001, selectively sensitize ECs to radiation by decreasing cell survival
To determine whether inhibition of mTOR sensitizes GL261 cells and HUVEC to radiotherapy, clonogenic assays were performed. Both GL261 and HUVEC were treated with either 100 nM of rapamycin, 5 nM of Rad001, or a DMSO control and incubated for 1 h. This was followed with escalating radiation doses from 0 to 7 Gy. The rapamycin, Rad001, or DMSO was washed off after irradiation. After 2 weeks, colonies were stained and the scored colonies were graphed.
Cells treated with rapamycin or Rad001 alone had reduced plating efficiency. Interestingly, rapamycin and Rad001 significantly lowered the survival curve of irradiated HUVEC but only had little effect on GL261 cells as shown in Figure 1 .
Irradiation induces mTOR signaling in ECs
In order to determine whether irradiation activates the mTOR signaling pathway in ECs, HUVEC were irradiated with 3 Gy and phosphorylated mTOR protein levels were measured by Western immunoblots, which were probed for with p-mTOR antibody at the indicated time points. As shown in Figure 2a , phosphorylated mTOR was increased at 15 min following treatment with 3 Gy in HUVEC. The increase in phospho-mTOR persisted at 1 h after irradiation, without detectable change of total mTOR protein during these time points. In contrast, there was no increase of phospho-mTOR in GL261 cells at 30 min following irradiation. In order to establish whether activation of mTOR signaling was mediated by PI3K, the downstream marker of mTOR signaling, phospho-S6 was determined. HUVEC were treated with LY294002 (3 mM), a known PI3K inhibitor or Rad001 (50 nM). At 30 min after treatment with either inhibitor, cells were treated with 3 Gy of radiation. Cell lysates were then collected and analysed by gel electrophoresis, using antibody for phospho-S6 and total S6 protein. As shown in Figure 2b , HUVEC treated with 3 Gy showed increased levels of S6 phosphorylation.
Figure 1 mTOR inhibition radiosensitizes HUVEC but not GL261 cells. GL261 and HUVEC were treated with 100 nM of rapamycin, 5 nM of Rad001, or DMSO for 1 h. Cells were then irradiated with indicated doses of radiation and media was changed. After 2 weeks, colonies were scored. Survival curves for GL261 (a) and HUVEC (c) treated with radiation alone and radiation with rapamycin (100 nM) at the indicated radiation doses, and GL261 (b) and HUVEC (d) treated with radiation alone and radiation with Rad001 (5 nM) at the indicated radiation doses are shown mTOR as a therapeutic target ET Shinohara et al Cells treated with LY294002 or Rad001 alone showed very little S6 phosphorylation with or without irradiation, similar to nonirradiated HUVEC.
mTOR inhibition induces apoptosis in HUVEC
To determine whether mTOR inhibition induces apoptosis in HUVEC, we used Western analysis to probe for cleaved caspase 3. HUVEC were treated with vehicle (DMSO), 3 Gy, Rad001 (50 nM), and Rad001 with 3 Gy. Cells were treated with Rad001 one hour prior to radiation and proteins were collected 6 h later. Cleaved caspase 3 and total caspase 3 were probed for as shown in Figure 2c . DMSO alone showed no induction of caspase 3 cleavage, whereas there was minor induction of caspase 3 cleavage in cells treated with 3 Gy or Rad001 alone. However, combined therapy with Rad001 and 3 Gy resulted in the greatest increase in caspase 3 cleavage when compared with the other groups. Total caspase 3 showed no change in all groups.
Rapamycin sensitizes vascular endothelium to radiation injury in in vitro and in vivo studies Since rapamycin reduced the survival of HUVEC, we studied rapamycin effects on tumor angiogenesis. HUVEC were treated with either 100 nM rapamycin or DMSO for 1 h. Cells were then irradiated with 0 or 3 Gy. Rapamycin and DMSO were washed off after irradiation. The EC morphogenesis assay was performed to examine the ability of the treated HUVEC to produce tubular structures in vitro. As shown in Figure 3 , HUVEC that were treated with both rapamycin and 3 Gy formed 3-4-fold less tubular structures, in contrast to the DMSO group. The groups treated with radiotherapy or rapamycin alone had nearly a onefold reduction of tubular structure.
Color Doppler Sonography (CDS) was used to determine the in vivo effects of these various treatment regimens on tumor neovascularization over the course of treatment. At the onset of treatment, all tumors in the respective groups showed a moderate amount of vascularity, as indicated by the representative image of a control tumor at the onset of treatment (Figure 4 ). After 11 days of tumor progression, control tumors displayed a significant increase in CDS signal. This signal was increased with respect to the tumor volume. The tumor volume is defined, and the number of color pixels within the tumor is compared to the noncolored pixels in the tumor volume. Tumors receiving radiation therapy alone demonstrated a lesser increase in CDS, whereas tumors receiving systemic RAD001 at a dose of 2.5 mg/ kg alone exhibited little change in CDS. Tumors receiving concomitant radiation and RAD001 demonstrated an appreciable diminution in CDS signal over the course of treatment. As these are just subjective pictures, we then used software to analyse vascularity and blood flow.
The quantified calculations of color pixel density (CPD) and mean power of color pixels (MPCP) for each group of mice are graphed in Figure 4 . They were consistent with the increases and decreases subjectively ascertained from the sonographic images. CPD is an indicator of in vivo tumor vascular density, whereas MPCP is more indicative of blood flow through the tumor. In the tumor peripheral zones, the subjects that received no treatments demonstrated a 95% overall increase in CPD (Po0.001) and a 48% increase in MPCP (Po0.03). For the mice that received radiation therapy alone, tumors demonstrated relatively less vascular growth than those of the control mice, with increases of 31% for CDP and 17% for MPCP. Tumors receiving Rad001 demonstrated even more restricted neovascularization and only small changes in these calculations, namely an 8% decrease in CDP and a 1% increase in MPCP. The group of mice receiving combination therapy were the only treatment group to express significant decreases in blood supply, with a 32% reduction in CDP (Po0.05) and 36% reduction in MPCP (Po0.03). Doppler studies results were confirmed with histological sections stained for von-willebrand Factor (vWF). Mice implanted with GL261 tumors were treated in an analogous fashion as the mice used in the Doppler study, with daily Rad001 (2.5 mg/kg) and 3 Gy treatments. After 5 days, the mice were killed and tumors were collected and paraffin fixed. To quantify blood vessels, sections were stained with vWF and the number of vessels per Â 400 field was determined for each treatment group. Each treatment group had three Â 400 areas counted and the number of vessels attributed to that treatment group was the average of those three counts. 
Rapamycin enhanced radiation-induced tumor regression
To determine whether inhibition of mTOR enhances radiation-induced tumor volume regression, GL261 glioma xenograft were established and tumor volumes were measured by use of calipers, as described previously (Edwards et al., 2002) . GL261 tumor-bearing mice were treated with 3 Gy twice a week for 2 weeks. Rapamycin was given orally at a dose of 2 mg/kg prior to radiotherapy. As shown in Figure 6 , the prescribed doses of radiotherapy or rapamycin were effective in controlling the growth of GL261 xenografts. Rapamycin given with radiation induced tumor growth delays of 18 days and 15 days, respectively, when compared with radiation alone.
Discussion
In the present study, we have shown that irradiation activates mTOR signaling in vascular endothelium, and that this activation is mediated by PI3K; however, similar activation is absent in GL261 cells. mTOR inhibitors radiosensitize HUVEC but not GL261 glioma cells.
mTOR is becoming an important target for a new line of anticancer drugs such as CCI-779 and RAD001, which are derived from rapamycin and exhibit significant anticancer activity in various tumor cell lines (Huang and Houghton, 2003; Boulay et al., 2004) . The activation of mTOR enhances protein translation via phosphorylating eucaryotic initiation factor 4E-binding Rad001 with radiation reduces vascular density in glioma tumor models: GL261 tumors were grown in mice, and they were treated with Rad001 (2.5 mg/kg) and 3 Gy of radiation daily, for a total of 5 days. Tumors were resected and paraffin fixed. Blood vessels were stained for using an antibody for vWF. Representative sections from each treatment group are shown at Â 400 magnification (a). Average blood vessel density of each treatment group was determined by counting the number of blood vessels in a Â 400 field. This was repeated three times and the average of the three values was plotted as shown in (b . S6 phosphorylation has been used as a biomarker for mTOR activation (Eshleman et al., 2002) . mTOR may be essential for the survival of glioma since certain glioma cell lines were shown to be sensitive to rapamycin and its derivatives (Hosoi et al., 1998) . Furthermore, rapamycin has been reported to sensitize U87 glioma xenografts to radiotherapy (Eshleman et al., 2002) . Consistent with our results, Eshleman et al. also found that a monolayer of glioma cells treated with rapamycin had no change in radiosensitivity. Eshleman et al. (2002) also showed that when glioma cells were grown in spheroids, treatment with rapamycin induced radiosensitization and the authors propose that this effect may be due to rapamycin improving the oxygenation of the spheroids. This study demonstrated that there is a radiosensitizing effect intrinsic to the tumor mass that is independent of the host component (Eshleman et al., 2002) . However, they also postulated that the host component was important in the improved tumor growth delay observed in animals treated with rapamycin and radiation (Eshleman et al., 2002) . In our study, we addressed the role of the host component of glioma and more specifically the effects of rapamycin on the radiosensitivity of gliomal vasculature. We found that rapamycin and Rad001 failed to induce radiosensitization in GL261 monolayers, in agreement with Eshleman et al. (2002) . In contrast, the radiosensitizing effect of mTOR inhibition on HUVEC monolayers was shown in colony assays. Further evidence that mTOR inhibition is an effective vascular radiosensitizer is found in previous studies that have shown that rapamycin inhibits angiogenesis, likely by reducing VEGF expression (Guba et al., 2002) . Geng et al. (2001) have shown that VEGF inhibition has a radiosensitizing effects on tumor vasculature. Further studies have suggested that reduced VEGF expression may induce its antiangiogenic effects in an S6-dependent fashion (Yu and Sato, 1999) . These findings suggest that in addition to the direct effects of rapamycin on tumor cells in in vivo models, rapamycin is also causing an antiangiogenic effect.
To the authors' knowledge, this is the first study to demonstrate the radiosensitizing effects of rapamycin on the host vasculature. Results from in vitro EC tubule formation assays suggest that mTOR inhibition augments the effects of radiation on vascular endothelial migratory ability. These results indicated that rapamycin had significant inhibitory effects on tubule formation, consistent with rapamycin's antiangiogenic effects shown by Guba et al. (2002) . Doppler data supports this with additional in vivo data. Results indicated significant reduction in vascularity and flow of tumors treated with mTOR inhibitors alone, also consistent with Guba et al. (2002) . This reduction in vasculature was confirmed with our histological data which indicated that glioma tumors in mice that have been treated with Rad001 and radiation had a greater reduction in vascular density compared with tumors which had been treated with Rad001 or radiation alone. We have shown that radiation used in combination with mTOR inhibitors had an even greater effect on the tumor vasculature when compared with either treatment alone. From these results, we propose that mTOR inhibitors are an important radiosensitizer in the vascular endothelium. Tumor volume study results in mice further support this, with a significant increase in growth delay in mice treated with rapamycin and radiation compared with either treatment alone, consistent with the findings of Eshleman et al.
The difference between GL261 and HUVEC response to radiation given with mTOR inhibitors has several explanations. Several different mutations and differences in protein expression have been found to be linked to how cells respond to mTOR inhibition . Malignant cell lines show a remarkable variance in sensitivity to rapamycin, displaying a several thousand-fold difference in intrinsic sensitivity (Dilling et al., 1994) . However, the vascular endothelium provides a consistent target across both different cell lines and the heterogenicity within a cancer type. Furthermore, whether rapamycin induces a cytotoxic, cytostatic, or a cytotoxic/cytostatic response appears to be cell line dependent (Hosoi et al., 1998 (Hosoi et al., , 1999 . ATM (Beamish et al., 1996) , p53 , and phosphate and tensin homologue deleted on chromosome 10 (PTEN) (Majumder et al., 2004) have all been linked to rapamycin resistance. PTEN is mutated in 20-30% of glioblastoma (Li et al., 1997; Duerr et al., 1998) . Low expression levels of PTEN were associated with poor patient survival, possibly by upregulating Akt (Ermoian et al., 2002) . PTEN gene transfer results in inhibition of S-phase entry in glioblastoma cells (Cheney et al., 1999) , reduced growth and angiogenesis in mouse glioma models (Wen et al., 2001) , and sensitization to irradiation in glioma cell cultures (Wick et al., 1999) . P53 mutations are the most common abnormality in human malignancy (Gaidano et al., 1991) and p53 is mutated in approximately one third of gliomas (Newcomb et al., 1993; Lang et al., 1994) .
Additional defects that may lead to resistance in certain cell lines include defects in FKBP12 and the FRB domain. To bind to the FRB domain and inhibit mTOR, rapamycin must first bind to FKBP12. Mutations in either the FKBP12 protein (Dumont et al., 1995) or the FRB domain (Chen et al., 1995; Dumont et al., 1995) attenuate rapamycin binding ability. Downstream targets of mTOR may also be mutated or have a decrease in production leading to rapamycin resistance. S6K1 is a major downstream target of mTOR and several mutation in S6K1 phosphorylation sites are associated with resistance to rapamycin (Dennis et al., 1996) . Another protein, 4E-BP1, a suppressor of eIF4E, is also known to be a downstream target of mTOR . Recently, it has been shown that decreased levels of 4E-BP1 are also associated with rapamycin resistance (Dilling et al., 2002) . Differences in these proteins may also explain the different response between GL261 and HUVEC. It also provides a rational for focusing on the vascular endothelium for radiosensitization due to less heterogeneity across patients.
In summary, our data suggest that irradiation activates mTOR cell survival signaling in glioma vascular endothelium via a PI3K/Akt-dependent pathway. mTOR inhibition resulted in marked increase in radiosensitization of HUVEC with little sensitization of GL261 cells. Rapamycin's effects on vascular endothelium were further confirmed with tubule formation, Power Doppler, and vWF staining studies, which indicated that vascular endothelium was affected in both in vitro and in vivo. We demonstrated that mTOR inhibitors are an effective radiosensitizer in the GL261 glioma model.
Materials and methods

Cell culture
HUVEC were obtained from Clonetics and were maintained in EBM-2 medium supplemented with EGM-2 MV single aliquots (BioWhittaker). GL261 cells were maintained in DMEM with Nutrient Mixture F-12 1 : 1 (Life Technologies, Inc.) with 7% FCS, 0.5% penicillin-streptomycin, and 1% sodium pyruvate. All cells were incubated in a 371C in a 5% CO 2 incubator. Irradiation was given, by use of a Cobalt-60 radioactive source. Rapamycin was purchased from Sigma and Rad001 was kindly provided by Dr Heidi Lane (Novartis).
Western immunoblots
Cells were treated or irradiated according to the individual study (Doses: LY294002 3 mM, RAD001 50 nM). At the time of harvest, cells were counted and then washed with ice-cold PBS twice before the addition of lysis buffer. Equal amounts of protein were loaded into each well and separated by 10% SDS-PAGE gel. Blots were incubated with the rabbit-antiphospho-mTOR (Ser2448), total mTOR, cleaved caspase 3, total caspase 3, b-actin, phospho-S6, total-S6, antibodies (Cell Signaling) overnight at 41C. Goat anti-rabbit IgG secondary antibody (1 : 1000; Amersham) was incubated for 1 h at room temperature. Immunoblots were developed by using the enhanced chemiluminescence (ECL) detection system (Amersham) according to the manufacturer's protocol and autoradiography.
In vitro clonogenic assay HUVEC and GL261 cells were treated with either rapamycin at a dose of 100 nM, Rad001 at a dose of 5 nM, or DMSO control for 1 h. Cells were irradiated and medium was changed. After irradiation, cells were returned to 371C incubation and maintained for 2 weeks. Cells were then fixed for 15 min with 3 : 1 methanol : acetic acid and stained for 15 min with 0.5% crystal violet (Sigma) in methanol. After staining, colonies were counted with a cutoff of 50 viable cells. Surviving fraction was calculated as (mean colony counts)/(cells inoculated) Â (plating efficiency), where plating efficiency was defined as (mean colony counts)/(cells inoculated for unirradiated controls).
Tumor volume assessment C57BL/6 mice received subcutaneous injection of one million GL261 cells into the right hind limb. After 7-10 days when average tumor volume reached 0.2 cm 3 , mice were stratified into groups (five mice per group), so that the mean tumor volume in each group was comparable. Mice were then treated with rapamycin at a dose of 2 mg/kg (Eshleman et al., 2002) . Treatment groups consisted of DMSO control, rapamycin alone, radiotherapy alone, and rapamycin þ radiotherapy, respectively. The radiation groups received 12 Gy of radiation, given as 3 Gy fractions over 14 days (twice a week), using a Cobalt irradiator to the tumor with the remainder of the body shielded with lead. Rapamycin was administered orally at a dose of 2 mg/kg prior to radiotherapy and twice a week after the completion of radiotherapy. Tumor volume measurements began on treatment day 1 and continued twice a week until the tumor volumes became 10% of the body size. Measurements were made using skin calipers, as previously described (Edwards et al., 2002) . Tumor volumes were calculated using a formula (a Â b Â c/2) that was derived from the formula for an ellipsoid. Data were calculated as the percentage of the original (day 1) tumor volume and graphed as percent change in tumor volume7s.d. for each treatment group.
Histological sections and vWF staining
Mice were implanted with GL261 as described above in the tumor volume studies. After 7-10 days, mice in the drug treatment group were then treated with 2.5 mg/kg of Rad001, p.o. daily (Boulay et al., 2004) . Mice in the radiation treatment group were treated with 3 Gy daily fractions, administered by cobalt irradiator as described above in the tumor volume studies. After 5 days of daily treatments, mice were killed and tumors were paraffin fixed. Slides from each treatment group were then stained for vWF using anti-vWF polyclonal antibody (Chemico). Blood vessels were quantified by randomly selecting a Â 400 field and counting the number of blood vessels per field. This was carried out in triplicate and the average of the three counts was calculated. CDS C57BL/6 mice were implanted with tumors as described in the tumor volume methods. Mice were treated with oral RAD001 at a dose of 2.5 mg/kg as described above. Tumor models in the four treatment groups underwent noninvasive color Doppler sonographic (CDS) imaging to quantitatively assess tumor blood flow, using a 10-5 MHz linear array Entos probe attached to an HDI 500 ultrasound scanner (ATL/Philips, Bothell, WA, USA). CDS images were obtained with a power gain of 82%. Care was taken to minimize motion artefact during image acquisition. A 10-s cineloop of the entire tumor area was obtained with the transducer positioned perpendicularly to the long axis of the lower extremity. Postprocessing of tumor images with HDI-lab software (ATL/Philips) allowed for the calculations of color pixel density (CPD ¼ (# of color pixels in tumor region)/(total # of pixels in tumor region)) and mean power of color pixels (MPCP ¼ (sum of color pixel intensities in region)/(total area of color pixels in region)) for individual regions of interest. Regions of interest were manually defined for (1) the entire tumor area and (2) the superficial peripheral zone at the edge of the tumor. These measurements were acquired at two time points over the course of tumor growth to longitudinally assess changes in tumor blood flow and vascularity.
Mean values of CDP and MPCP for each of the four groups of mice before and after treatment were calculated, and the Student's unpaired t test was employed to make statistical comparisons for vascularity before and after treatment. P-values of less than 0.5 were considered significant.
